X
Xiaochun Zhang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 7
Citations - 396
Xiaochun Zhang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Clonogenic assay & Cancer. The author has an hindex of 6, co-authored 7 publications receiving 340 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer
Maria Angelica Cortez,David Valdecanas,Xiaochun Zhang,Yanai Zhan,Vikas Bhardwaj,George A. Calin,Ritsuko Komaki,Dipak Giri,Caio C. Quini,Tatiana Wolfe,Heidi J. Peltier,Andreas G. Bader,John V. Heymach,Raymond E. Meyn,James W. Welsh +14 more
TL;DR: It is found that miR-200c overexpression increased cellular radiosensitivity by direct regulation of the oxidative stress response genes PRDX2, GAPB/Nrf2, and SESN1 in ways that inhibits DNA double-strand breaks repair, increase levels of reactive oxygen species, and upregulate p21.
Journal ArticleDOI
Treatment of Radioresistant Stem-Like Esophageal Cancer Cells by an Apoptotic Gene-Armed, Telomerase-Specific Oncolytic Adenovirus
TL;DR: Ad/TRAIL-E1 preferentially targets radioresistant CSC-like cells and resulted in significant tumor growth suppression and longer survival in Seg-1R–bearing mice, with no significant toxicity.
Journal ArticleDOI
Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation
TL;DR: CSC-like cells may be more sensitive to irradiation with protons than photons, and this increased sensitivity could be caused by the greater ROS generated by protons.
Journal ArticleDOI
Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer
TL;DR: The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved therapeutic efficacy in suppressing NSCLC tumor growth and prolonging survival and may improve the therapeutic ratio of radiotherapy inNSCLC.
Journal ArticleDOI
Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer.
TL;DR: It is shown for the first time that CAR is a marker of cancer stem cells and may affect the activities of CSCs in treatment-resistant NSCLC and may prove to be a target for CSC treatment and a predictor of treatment response in patients with NSCLCs.